Drug intelligence / Profile preview

PHY906

Development stage: Phase 2
Lead developer: Yiviva
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**PHY906** is an orally administered, pharmaceutical-grade four-herb botanical formulation developed from the traditional Chinese medicine formula Huang Qin Tang and subsequently renamed **YIV-906**. It contains standardized aqueous extracts of *Scutellaria baicalensis*, *Glycyrrhiza uralensis*, *Paeonia lactiflora*, and *Ziziphus jujuba*. PHY906 is being developed as a multi-target immunomodulatory and gastrointestinal cytoprotective adjunct to anticancer therapy, with the goal of enhancing antitumor activity while reducing chemotherapy- or chemoradiation-associated gastrointestinal toxicity. Clinical studies have evaluated PHY906 with capecitabine in pancreatic cancer and hepatocellular carcinoma, with irinotecan-based chemotherapy in colorectal cancer, and with chemoradiation in rectal cancer. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/chinese-herbal-formulation-phy906))

Brand names: YIV-906YIV906YIV 906
Other names: Chinese herbal formulation PHY906

Targets

GUSB (Beta-glucuronidase)NOS2 (Nitric Oxide Synthase 2)CYP3A4 (Cytochrome P450 3A4)IDO1 (Indoleamine 2,3-dioxygenase 1)

Beyond the preview

Go deeper on PHY906.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHY906.

Explore the full profile